Navigation Links
AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
Date:11/16/2010

ALISO VIEJO, Calif., Nov. 16, 2010 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  Jefferies & Company, Inc. is acting as sole book-running manager in the offering and Canaccord Genuity Inc., Wedbush PacGrow Life Sciences, Summer Street Research Partners, and Merriman Capital are acting as co-managers for the offering.  In addition Trout Capital LLC is serving as a financial advisor to AVANIR.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  

A registration statement relating to the shares of common stock issued in the offering has been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A preliminary prospectus supplement relating to the offering will be filed with the SEC.  Copies of the preliminary prospectus supplement relating to these securities may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at (877) 547-6340, and at Prospectus_Department@Jefferies.com.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Forward Looking Statements

Statements in this press release that are not historical facts, including statements that are preceded by, followed by,
'/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AVANIR to Present at the Canaccord Genuity Growth Conference
2. AVANIR to Present at the Wedbush Life Sciences Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
5. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
6. Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
7. ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010
8. Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
9. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
10. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MD (PRWEB) November 21, 2014 ... management solutions provider, has released Limfinity® version 5.1.4. ... installation projects of Limfinity® than ever in RURO’s ... configuration and minority framework enhancement. Limfinity® version 5.1.4 ... far above and beyond bug fixes! , Limfinity® ...
(Date:11/22/2014)... 21, 2014  The element of surprise has been ... they strike without warning. Until now, epidemiologists had nothing ... viral outbreak, resulting in suboptimal responses to both the ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... removed because virus gene structural changes have been found ...
(Date:11/21/2014)... (PRWEB) November 19, 2014 The science ... lives was shared with more than 200 primary students ... students from the University of Otago Physics Department and ... The Otago students, members of the university’s OSA/SPIE Student ... in early September, giving children from small, rural schools ...
(Date:11/21/2014)... The report, "Synthetic Biology Market by ... Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & ... Global Forecast to 2018", analyses and studies ... challenges. , Browse 99 market data tables ... and in-depth TOC of the global synthetic ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2Viruses' Advantage of Surprise is Lost 2Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4
... , NEW YORK and MONTREAL, Dec. 21 /PRNewswire-FirstCall/ ... be targeting U.S. state and municipal regulatory bodies for the ... , "BioSpec Global Solutions will be moving to target regulatory ... " Given the advantages not only on time advantage (10 ...
... , - Company,s results amongst the best for influenza ... /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today ... clinical trial with its H5N1 Avian Influenza vaccine candidate ...
... Security personnel need to be able to find explosive ... them. To aid such searches, the National Institute of ... of Homeland Security, has developed a new certified reference ... Compatible with field and laboratory assay methods, the SRM ...
Cached Biology Technology:BioSpec Global Solutions Inc. target market TOGS 9000 to state and municipal regulatory bodies in U.S. market 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 3Medicago reports positive Phase I results for its avian flu pandemic vaccine 4New NIST trace explosives standard slated for homeland security duty 2
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... (BUSM) study shows a mind-body class elective for medical ... thoughts and tasks more effectively. The study, published in ... innovative course may help medical students better manage stress ... their patients. Allison Bond, MA, a third-year medical ...
... drug has shown promise in treating influenza, preventing lung injury ... University of Maryland School of Medicine researchers publishing in the ... that a drug called Eritoran can protect mice from death ... influenza virus. The potential value of this drug as single ...
... of Southampton has investigated public perception of how waste ... opinion of waste management facilities can influence where sites ... Obtaining the support of communities around municipal solid ... successful operation of these services. One common complaint from ...
Cached Biology News:BUSM study shows positive impact of mind-body course on well-being of medical students 2University of Maryland School of Medicine researchers find potential novel treatment for influenza 2Odor and environmental concerns of communities living near waste disposal facilities 2
... described by end-users to be "a delight ... of light microscopy and electronic imaging. With ... does not require much space and can ... environment. The DM-BA300 combines Motic's own revolutionary ...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
... Aquarius 384 is a compact and ... head is a unique flow-through device, ... the included wash system. Optional ... stacker system. Will be upgradable ...
Biology Products: